Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled time : 18:00 save search
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $19.08 0.85% 0.84% 450K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $18.04 0.5% 0.44% 400K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
Published: 2022-11-28 (Crawled : 18:00) - precisionbiosciences.com
DTIL | $11.51 -10.57% -11.91% 220K
|
Health Technology
|
| O: -0.71%
H: 2.88%
C: -2.88%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: -0.6%
pbcar0191 t-cell
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
immunotherapy meeting cancer
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: -5.85%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
incb9928 collaboration trial therapeutics tumors agreement
M&A Frenzy: Incyte & Villaris, AmplifyBio & PACT, Estrella Earns Nasdaq Listing (Updated)
Published: 2022-10-03 (Crawled : 18:00) - biospace.com/
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.74%
H: 2.89%
C: 2.53%
nasdaq
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants
Published: 2021-09-02 (Crawled : 18:00) - biospace.com/
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 1.14%
H: 0.17%
C: -1.35%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.23%
H: 0.65%
C: 0.03%
GLPG | News | $29.22 -0.92% -0.82% 180K
|
Health Technology
|
| O: 2.59%
H: 1.24%
C: 0.81%
fda drug pharma
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment
Published: 2021-07-14 (Crawled : 18:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.21%
H: 0.61%
C: 0.24%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.24%
H: 0.11%
C: -1.16%
commercialization china
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
phase 2
Exocrine Pancreatic Insufficiency Market Anticipated to Soar Modestly with a CAGR 7.21% During the Study Period 2018-30 in the 7MM, Estimates DelveInsight
Published: 2021-03-24 (Crawled : 18:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.01%
H: 0.07%
C: -1.92%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.61%
H: 0.39%
C: -1.11%
pancreatic pancreas exocrine pancreatic insufficiency
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.